Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

KRAS P.G12C
Non Small Cell Lung Cancer

Interventions

DRUG: Sotorasib 120Mg Tab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris